DRREDDY.BO — Dr. Reddy's Laboratories Limited (Stock)

Price: $1225.85 · 1 day: +0.42% · 5 days: +2.66% · 1 month: +7.13% · YTD: -2.13%
As of 2026-10-16 08:51 UTC.

52-week range: $1025.9 – $1377.95 (currently at 57% of the range).

The brief

DRREDDY.BO is in a turning down, momentum firm. $1243.81 is the level overhead; $1201.6 the first support below.

3 of 6 technical checks lean bullish.

• Price vs 50-day: above
• Price vs 200-day: below
• 50d vs 200d avg: below
• MACD: bullish
• RSI momentum: 55
• 5-day tape: +2.7%

Key levels

Indicators

Next earnings: 2026-10-23.

Latest DRREDDY.BO news

• Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month — Piramal Pharma Solutions (PPS) and nonprofit generic drug manufacturer NP2 announced plans to complete the drug development phase of the generic cancer drug cyclophosphamide in October, with manufacturing to occur at PPS (PR Newswire, 2026-09-30)
• Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month — Piramal Pharma Solutions (PPS) and nonprofit NP2 announced plans to complete the drug development phase of the generic cancer drug cyclophosphamide in October, with manufacturing to occur at PPS's Lexington, Kentucky fac (PR Newswire, 2026-09-30)
• Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility — Piramal Pharma Solutions, a subsidiary of Piramal Pharma Ltd., announced a CAD 1.75 million investment from the Ontario government's Life Sciences Scale-Up Fund for its Aurora, Canada facility. The company will invest a (PR Newswire, 2026-09-29)
• Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility — Piramal Pharma Solutions, a subsidiary of Piramal Pharma Ltd., announced a CAD 1.75 million investment from the Ontario government's Life Sciences Scale-Up Fund for its Aurora, Canada facility. The company will invest a (PR Newswire, 2026-09-29)
• Health Care Roundup: Market Talk — The Wall Street Journal's Health Care Roundup provides brief market commentary on the sector, including a note on Eurofins Scientific's 2027 profitability improvement target. The article is a compilation of short updates (The Wall Street Journal, 2026-09-29)
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY — Pomerantz LLP has launched an investigation into Dr. Reddy's Laboratories Limited (NYSE: RDY) regarding potential securities fraud or unlawful business practices by the company and certain officers. The probe follows Dr. (PR Newswire, 2026-09-24)
• Obesity Drug Costs Drive Division in Corporate America — The article highlights growing corporate division over the cost of GLP-1 obesity drugs, noting that unlike typical new medications, these treatments may not gain broader insurance coverage over time. The financial burden (Bloomberg Business, 2026-09-24)
• Global Vitiligo Treatment Market to Reach USD 2.97 Billion by 2034 at 5.8% CAGR as Rising Disease Prevalence, Growing Aesthetic Awareness, and Advances in Targeted Therapies Accelerate Market Growth, Reports Maximize Market Research — Maximize Market Research projects the global vitiligo treatment market will grow from USD 1.79 billion in 2025 to USD 2.97 billion by 2034, reflecting a 5.8% CAGR. Growth is driven by rising disease prevalence, increased (PR Newswire, 2026-09-23)

Explore more

Interactive DRREDDY.BO chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs